$2.53T
Total marketcap
$189.93B
Total volume
BTC 50.01%     ETH 15.90%
Dominance

Exelixis EXEL Stock

23.17 USD {{ price }} 0.826808% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
7.03B USD
LOW - HIGH [24H]
23.07 - 23.42 USD
VOLUME [24H]
2.29M USD
{{ volume }}
P/E Ratio
35.64
Earnings per share
0.65 USD

Exelixis Price Chart

Exelixis EXEL Financial and Trading Overview

Exelixis stock price 23.17 USD
Previous Close 18.78 USD
Open 18.81 USD
Bid 0 USD x 1400
Ask 0 USD x 1300
Day's Range 18.77 - 19.14 USD
52 Week Range 14.87 - 22.47 USD
Volume 2.61M USD
Avg. Volume 2.76M USD
Market Cap 6.22B USD
Beta (5Y Monthly) 0.67676
PE Ratio (TTM) 41.52174
EPS (TTM) 0.65 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 25.4 USD

EXEL Valuation Measures

Enterprise Value 4.99B USD
Trailing P/E 41.52174
Forward P/E 20.319149
PEG Ratio (5 yr expected) 1.12
Price/Sales (ttm) 3.7380724
Price/Book (mrq) 2.4294074
Enterprise Value/Revenue 2.999
Enterprise Value/EBITDA 29.295

Trading Information

Exelixis Stock Price History

Beta (5Y Monthly) 0.67676
52-Week Change 2.90%
S&P500 52-Week Change 20.43%
52 Week High 22.47 USD
52 Week Low 14.87 USD
50-Day Moving Average 19.27 USD
200-Day Moving Average 17.51 USD

EXEL Share Statistics

Avg. Volume (3 month) 2.76M USD
Avg. Daily Volume (10-Days) 2.87M USD
Shares Outstanding 325.64M
Float 294.13M
Short Ratio 2.97
% Held by Insiders 2.41%
% Held by Institutions 92.26%
Shares Short 7.1M
Short % of Float 2.47%
Short % of Shares Outstanding 2.18%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 9.24%
Operating Margin (ttm) 8.83%
Gross Margin 96.45%
EBITDA Margin 10.23%

Management Effectiveness

Return on Assets (ttm) 3.17%
Return on Equity (ttm) 6.34%

Income Statement

Revenue (ttm) 1.66B USD
Revenue Per Share (ttm) 5.16 USD
Quarterly Revenue Growth (yoy) 14.79%
Gross Profit (ttm) 1.55B USD
EBITDA 170.31M USD
Net Income Avi to Common (ttm) 153.74M USD
Diluted EPS (ttm) 0.46
Quarterly Earnings Growth (yoy) -41.60%

Balance Sheet

Total Cash (mrq) 1.31B USD
Total Cash Per Share (mrq) 4.03 USD
Total Debt (mrq) 186.95M USD
Total Debt/Equity (mrq) 7.32 USD
Current Ratio (mrq) 4.999
Book Value Per Share (mrq) 7.862

Cash Flow Statement

Operating Cash Flow (ttm) 299.3M USD
Levered Free Cash Flow (ttm) 135.46M USD

Profile of Exelixis

Country United States
State CA
City Alameda
Address 1851 Harbor Bay Parkway
ZIP 94502
Phone 650 837 7000
Website https://www.exelixis.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 1223

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Q&A For Exelixis Stock

What is a current EXEL stock price?

Exelixis EXEL stock price today per share is 23.17 USD.

How to purchase Exelixis stock?

You can buy EXEL shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Exelixis?

The stock symbol or ticker of Exelixis is EXEL.

Which industry does the Exelixis company belong to?

The Exelixis industry is Biotechnology.

How many shares does Exelixis have in circulation?

The max supply of Exelixis shares is 303.19M.

What is Exelixis Price to Earnings Ratio (PE Ratio)?

Exelixis PE Ratio is 35.64615600 now.

What was Exelixis earnings per share over the trailing 12 months (TTM)?

Exelixis EPS is 0.65 USD over the trailing 12 months.

Which sector does the Exelixis company belong to?

The Exelixis sector is Healthcare.

Exelixis EXEL included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD